Aerpio Therapeutics raises $27 million for novel diabetic macular edema drug
This article was originally published in Scrip
Aerpio Therapeutics, the Cincinnati, Ohio-based company, raised $27 million in a Series A financing round to fund its first-in-class Tie2 receptor activator AKB-9778 through 2014 when the company plans to complete a Phase II clinical trial in the treatment of diabetic macular edema (DME).
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.